$4.05
0.12% yesterday
Nasdaq, Nov 25, 09:48 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$4.04
+1.24 44.29% 1M
+1.41 53.61% 6M
-0.05 1.22% YTD
+1.42 54.20% 1Y
-6.43 61.41% 3Y
-0.99 19.68% 5Y
-5.71 58.56% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.01 0.25%
ISIN
US68621F1021
Symbol
ORGO
Sector

Key metrics

Market capitalization $535.61m
Enterprise Value $547.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 140.63
EV/Sales (TTM) EV/Sales 1.20
P/S ratio (TTM) P/S ratio 1.18
P/B ratio (TTM) P/B ratio 1.92
Revenue growth (TTM) Revenue growth 1.34%
Revenue (TTM) Revenue $455.04m
EBIT (operating result TTM) EBIT $11.95m
Free Cash Flow (TTM) Free Cash Flow $3.89m
Cash position $94.93m
EPS (TTM) EPS $-0.06
P/E forward negative
P/S forward 1.16
EV/Sales forward 1.18
Short interest 27.44%
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

Buy
75%
Hold
25%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
455 455
1% 1%
100%
- Direct Costs 130 130
7% 7%
28%
325 325
1% 1%
72%
- Selling and Administrative Expenses 238 238
0% 0%
52%
- Research and Development Expense 51 51
15% 15%
11%
37 37
20% 20%
8%
- Depreciation and Amortization 25 25
17% 17%
6%
EBIT (Operating Income) EBIT 12 12
52% 52%
3%
Net Profit -7.38 -7.38
157% 157%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Neutral
GlobeNewsWire
4 days ago
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the...
Neutral
GlobeNewsWire
11 days ago
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination
Neutral
Seeking Alpha
13 days ago
Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fisca...
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 862
Founded 1985
Website www.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today